News

POWL's fiscal Q3 earnings and revenues miss estimates, even as record orders and a $2.4 billion backlog strengthen its outlook.

RBC Bearings' fiscal first-quarter earnings and revenues top estimates as aerospace growth, VACCO and wider margins lift results.

IDEX (IEX) just released second quarter and first half 2026 results, along with an update on its long running share repurchase program, giving investors fresh numbers to evaluate the stock. See our latest analysis for IDEX. Recent earnings and buyback news come as IDEX trades at US$230.45, with the share price up 28.7% year to date and a 1 year total shareholder return of 46.98%. This points to momentum building over the past year despite a modest pullback in the last trading day. If you are...

Manufacturing company IDEX (NYSE:IEX) announced better-than-expected revenue in Q2 CY2026, with sales up 6.4% year on year to $920.6 million. Guidance for next quarter’s revenue was optimistic at $931.4 million at the midpoint, 2.1% above analysts’ estimates. Its non-GAAP profit of $2.32 per share was 10.1% above analysts’ consensus estimates.

IDEX (NYSE:IEX) reported second-quarter 2026 results that exceeded its expectations, supported by growth in its Health & Science Technologies segment, stronger orders and operational execution. The company raised its full-year outlook for organic sales growth, adjusted EBITDA margin and adjusted

Moby summary of IDEX Corporation's Q2 2026 earnings call

IDEX Corp (IEX) reports robust Q2 performance with significant order growth and raises full-year financial outlook.

IEX tops second-quarter estimates, posts record orders above $1 billion and raises its 2026 outlook as demand improved across key end markets.

The headline numbers for Idex (IEX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Idex (IEX) delivered earnings and revenue surprises of +10.48% and +2.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Manufacturing company IDEX (NYSE:IEX) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 6.4% year on year to $920.6 million. Guidance for next quarter’s revenue was optimistic at $931.4 million at the midpoint, 2.1% above analysts’ estimates. Its non-GAAP profit of $2.32 per share was 10.1% above analysts’ consensus estimates.

Manufacturing company IDEX (NYSE:IEX) will be reporting results this Wednesday before market hours. Here’s what investors should know.

IEX reports Q2 results on July 29, with revenue growth expected as Health & Science demand and acquisitions support sales despite cost pressures.

IDEX has risen 24.7% year to date, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to upside while earnings based multiples lean the other way. The 24.7% year to date gain suggests investors have been willing to pay a richer price for IDEX shares in a relatively short period. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock trades at about a 22.8% discount to projected cash flows, while market...

RBC Bearings (RBC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Idex (IEX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDEX Corporation enters Q2 earnings with strong momentum, as Wall Street watches for another solid performance.

Idex (IEX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IEX beats Q1 estimates and raises outlook as strong Health & Science Technologies demand and record orders signal momentum into 2026.

IDEX (NYSE:IEX) reported first-quarter 2026 results that management said came in above expectations, supported by growth in its targeted “advantage markets” and continued application of the company’s 80/20 operating philosophy. Quarterly performance and orders President and CEO Eric Ashleman said I

Moby summary of IDEX Corporation's Q1 2026 earnings call

IDEX delivered a strong first quarter and continue to see our growth strategies gain traction as we expand and integrate capabilities in targeted advantaged markets powered by 8020. In the first quarter, IDEX delivered organic sales growth of 5% and adjusted EBITDA margin of 26%, which reflects a margin expansion of 50 basis points year-over-year. Strength was most pronounced in our Health & Science Technologies, or HST segment, where secular drivers continue to fuel growth across high-value applications in data center, semiconductor and space and defense markets.

The headline numbers for Idex (IEX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Idex (IEX) delivered earnings and revenue surprises of +12.68% and +6.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?